替加环素治疗继发性不动杆菌血症的疗效及与治疗失败相关的因素。
Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.
作者信息
Liou Bo-Huang, Lee Yi-Tzu, Kuo Shu-Chen, Liu Po-Yu, Fung Chang-Phone
机构信息
Division of Infectious Diseases, Department of Medicine, Hsinchu Mackay Memorial Hospital, Hsinchu City, Taiwan.
Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
出版信息
Antimicrob Agents Chemother. 2015;59(6):3637-40. doi: 10.1128/AAC.04987-14. Epub 2015 Mar 30.
Abstract
We describe the clinical outcome of 17 patients with secondary Acinetobacter bacteremia whose isolates had a tigecycline MIC of ≤2 mg/liter and who received tigecycline within 2 days of bacteremia onset. The 14-day mortality rate of the tigecycline cohort was 41.2% (7/17), which was significantly higher than that of those receiving other appropriate antimicrobial agents (13.8%, 9/65; P = 0.018). However, the percentages of end-stage renal disease and congestive heart failure were higher in the tigecycline cohort. The efficacy of tigecycline was contingent upon the illness severity and bacterial species. Tigecycline should be applied cautiously for treatment of Acinetobacter bacteremia.
摘要
我们描述了17例继发性不动杆菌血症患者的临床结局，这些患者的分离株对替加环素的最低抑菌浓度（MIC）≤2mg/L，且在菌血症发作后2天内接受了替加环素治疗。替加环素组的14天死亡率为41.2%（7/17），显著高于接受其他合适抗菌药物治疗的患者（13.8%，9/65；P = 0.018）。然而，替加环素组终末期肾病和充血性心力衰竭的比例更高。替加环素的疗效取决于疾病严重程度和细菌种类。治疗不动杆菌血症时应谨慎使用替加环素。
相似文献
1
Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.
Antimicrob Agents Chemother. 2015;59(6):3637-40. doi: 10.1128/AAC.04987-14. Epub 2015 Mar 30.
2
Impact of reduced tigecycline susceptibility on clinical outcomes of Acinetobacter bacteremia.
J Microbiol Immunol Infect. 2018 Feb;51(1):148-152. doi: 10.1016/j.jmii.2017.08.024. Epub 2017 Oct 7.
3
Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
Scand J Infect Dis. 2013 Apr;45(4):315-9. doi: 10.3109/00365548.2012.732705. Epub 2012 Oct 31.
4
Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.
J Chemother. 2010 Apr;22(2):110-4. doi: 10.1179/joc.2010.22.2.110.
5
Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
Pharmacotherapy. 2007 Jul;27(7):980-7. doi: 10.1592/phco.27.7.980.
6
Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
J Microbiol Immunol Infect. 2016 Dec;49(6):924-933. doi: 10.1016/j.jmii.2015.06.009. Epub 2015 Aug 14.
7
Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia.
Int J Infect Dis. 2017 Aug;61:23-26. doi: 10.1016/j.ijid.2017.05.013. Epub 2017 May 29.
8
Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors.
Int J Infect Dis. 2017 Sep;62:26-31. doi: 10.1016/j.ijid.2017.06.023. Epub 2017 Jul 1.
9
The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii.
J Infect. 2011 Nov;63(5):351-61. doi: 10.1016/j.jinf.2011.08.001. Epub 2011 Aug 9.
10
Multidrug-resistant Acinetobacter baumannii bacteremia treated with tigecycline in two pediatric burn patients.
Pediatr Infect Dis J. 2015 Jun;34(6):677. doi: 10.1097/INF.0000000000000699.
引用本文的文献
1
treatment strategies: a review of therapeutic challenges and considerations.
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0106324. doi: 10.1128/aac.01063-24. Epub 2025 Jul 9.
2
Evaluating Risk Factors for Clinical Failure Among Tigecycline-Treated Patients.
Infect Drug Resist. 2024 Dec 4;17:5387-5393. doi: 10.2147/IDR.S496809. eCollection 2024.
3
Optimizing Treatment for Carbapenem-Resistant Complex Infections: A Review of Current Evidence.
Infect Chemother. 2024 Jun;56(2):171-187. doi: 10.3947/ic.2024.0055.
4
Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.
Clin Infect Dis. 2023 May 1;76(Suppl 2):S179-S193. doi: 10.1093/cid/ciad094.
5
High-Dose versus Standard-Dose Tigecycline Treatment of Secondary Bloodstream Infections Caused by Extensively Drug-Resistant : An Observational Cohort Study.
Infect Drug Resist. 2021 Sep 18;14:3837-3848. doi: 10.2147/IDR.S322803. eCollection 2021.
6
Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia.
Antimicrob Resist Infect Control. 2020 Sep 29;9(1):160. doi: 10.1186/s13756-020-00824-4.
7
Characterization of Extremely Drug-Resistant and Hypervirulent AB030.
Antibiotics (Basel). 2020 Jun 17;9(6):328. doi: 10.3390/antibiotics9060328.
8
Efficacy of intravenous tigecycline in patients with complex infections: results from 14 Phase III and Phase IV clinical trials.
Infect Drug Resist. 2017 Nov 3;10:401-417. doi: 10.2147/IDR.S143306. eCollection 2017.
9
Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00931-17. Print 2017 Sep.
10
The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.
Ann Clin Microbiol Antimicrob. 2017 Apr 5;16(1):24. doi: 10.1186/s12941-017-0199-8.
本文引用的文献
1
Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection.
Clin Infect Dis. 2012 Jul;55(2):209-15. doi: 10.1093/cid/cis385. Epub 2012 Apr 11.
2
Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes.
J Antimicrob Chemother. 2011 Aug;66(8):1839-46. doi: 10.1093/jac/dkr200. Epub 2011 Jun 8.
3
Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.
Clin Microbiol Infect. 2011 Dec;17(12):1798-803. doi: 10.1111/j.1469-0691.2011.03514.x. Epub 2011 May 20.
4
Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia.
Clin Infect Dis. 2011 Feb 1;52(3):352-60. doi: 10.1093/cid/ciq154. Epub 2010 Dec 30.
5
Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.
Clin Infect Dis. 2010 Jan 15;50(2):229-38. doi: 10.1086/648720.
6
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Diagn Microbiol Infect Dis. 2009 Jan;63(1):52-61. doi: 10.1016/j.diagmicrobio.2008.09.001. Epub 2008 Nov 5.
7
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Diagn Microbiol Infect Dis. 2008 Jul;61(3):329-38. doi: 10.1016/j.diagmicrobio.2008.04.009. Epub 2008 May 27.
8
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S354-67. doi: 10.1086/431676.
9
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S341-53. doi: 10.1086/431675.
Zotero 插件